Mainz Biomed, Thermo Fisher Collaboration

This is a US news story, published by Mainz Biomed, that relates primarily to Thermo Fisher’s news.

US news

For more US news, you can click here:

more US news

Thermo Fisher’s news

For more Thermo Fisher’s news, you can click here:

more Thermo Fisher’s news

emerging technologies news

For more emerging technologies news, you can click here:

more emerging technologies news

Mainz Biomed news

For more news from Mainz Biomed, you can click here:

more news from Mainz Biomed

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best tech news, business news, entertainment news, and much more. If you like emerging technologies news, you might also like this article about

Thermo Fisher Scientific

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Mainz Biomed develops market news, ready molecular genetic diagnostic solutions news, emerging technologies news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

diagnostic company

Mainz Biomed

•

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets - Mainz Biomed

Summary

Nutrition label

85% Informative

Mainz Biomed N.V. is a molecular genetics diagnostic company specializing in the early detection of cancer.

The collaboration will harness Thermo Fisher’s powerful technologies, instrumentation and information translation systems to enable Mainz to develop the proprietary assays for its next-generation CRC screening tests.

The company is currently running a pivotal FDA clinical study for US regulatory approval.

The following factors, among others, could cause actual results to differ from those described in these forward-looking statements.

Mainz Biomed undertakes no obligation to publicly update any.

statement made by us in this press release is based only on information currently available to Mainz .

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity